MELBOURNE (Reuters) - Australia will continue its inoculation programme with AstraZeneca PLC, health officials said on Saturday, after a blood clotting case raised concern about the safety of the vaccine. A 44-year-old man was admitted to a Melbourne hospital with clotting, days after receiving the AstraZeneca vaccine, suffering serious thrombosis, a condition that prevents normal blood flow though the circulatory system.
The Therapeutic Goods Administration (TGA) regulator and a panel, the Australian Technical Advisory Group on Immunisation (ATAGI), met late Friday and early Saturday to discuss further advice on the AstraZeneca vaccine.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
